# OnCo record keynote-057 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/keynote-057/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "keynote-057", "NCT02625961" ;
  schema:name "KEYNOTE-057"@en ;
  schema:description "KEYNOTE-057 showed that pembrolizumab could clear bladder cancer confined to the lining in a substantial minority of people whose disease had stopped responding to BCG, giving the first drug alternative to removing the bladder."@en ;
  schema:url <https://onco.cc/trials/keynote-057/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02625961> ;
  onco:status "positive" ;
  onco:tag "subtype-trials" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/non-muscle-invasive-bladder-cancer/>, <https://onco.cc/cancers/urothelial/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/merck/> ;
  onco:people <https://onco.cc/people/arjun-balar/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-keynote-057-lancet-oncol-2021/> .